Evan Dunn, MD
Ophthalmology · Wesley Chapel, FLNPI 1972879484
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,531 of the $20,529 with a category attached, or 61.0%. 31 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 26.0% of the total. Reporting peaked in 2024 at $5,819 and has fallen 58.8% since, to $2,398 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $84.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$5K
- Eyepoint US, Inc.$5K
- Alcon$2K
- Harrow Eye, LLC$1K
- Astellas Pharma US Inc$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$784
- plus $6K from 25 others
Across 34 payments — averaging $6337.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$163K
- Eyepoint US, Inc.$38K
- Astellas Pharma Global Development$14K
- Notal Vision, Inc.$570
What the payments were for
- Consulting fees$5,80528%
- Speaking & faculty fees$5643%
- Travel & lodging$1,6018%
- Food & beverage$12,53161%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 26 | $5,328 |
| Eyepoint US, Inc. | 15 | $4,793 |
| Alcon | 34 | $1,562 |
| Harrow Eye, LLC | 19 | $1,409 |
| Astellas Pharma US Inc | 24 | $1,130 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $784 |
| Genentech USA, Inc. | 24 | $707 |
| Notal Vision, Inc. | 5 | $650 |
| AbbVie(2 entities) | 13 | $624 |
| Alimera Sciences, Inc. | 23 | $486 |
| Amgen | 4 | $448 |
| Apellis Pharmaceuticals, Inc. | 7 | $342 |
| Mallinckrodt Hospital Products Inc. | 7 | $272 |
| Glaukos Corporation | 2 | $256 |
| Ivantis, Inc | 2 | $218 |
| Novartis | 9 | $180 |
| Rxsight Inc | 2 | $168 |
| NEW World Medical,inc. | 1 | $142 |
| Bausch & Lomb Americas Inc. | 2 | $135 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Dompe US, Inc. | 1 | $121 |
| Sight Sciences, Inc. | 1 | $120 |
| Coherus Oncology, Inc. | 2 | $99 |
| Sun Pharmaceutical Industries Inc. | 1 | $89 |
| Regeneron | 1 | $84 |
| Ocular Therapeutix, Inc. | 1 | $77 |
| ANI Pharmaceuticals, Inc. | 3 | $68 |
| Sandoz | 2 | $43 |
| Neurotech Pharmaceuticals, Inc. | 1 | $29 |
| Biogen | 1 | $27 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$4,558
- EYP-1901$4,123
- Izervay$509
- TRIESENCE$500
- STELLARIS$456
- Constellation$388
- IHEEZO$381
- YUTIQ$366
- TEPEZZA$351
- EYLEA HD$336
- Hydrus Microstent$226
- RXSIGHT CONTACT LENS$149
- RXSIGHT INJECTOR HANDPIECE$149
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$149
- RXSIGHT INJECTOR CARTRIDGE$149
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$149
- Unity$146
- Ahmed Glaucoma Valve$142
- Kahook Dual Blade$142
- EYSUVIS$125
How this compares
$20,529 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VabysmoFaricimab-Svoa | 100 | $272,019 |
| EyleaAflibercept | 22 | $63,121 |
| Eylea HdAflibercept | 15 | $55,125 |
| IzervayAvacincaptad Pegol Sodium/Pf | 14 | $33,600 |
| Prednisolone Acetate | 122 | $4,602 |
| Atropine Sulfate | 60 | $2,143 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 105 | $1,594 |
| Ketorolac Tromethamine | 46 | $1,294 |
| Difluprednate | 12 | $1,277 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 86 | $1,163 |
| Latanoprost | 90 | $825 |
| ErythromycinErythromycin Base | 46 | $520 |
| Brimonidine Tartrate | 27 | $390 |
| MoxifloxacinMoxifloxacin Hcl | 20 | $327 |
| Dorzolamide Hcl | 19 | $313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Vabysmo | $707 | $272,019100 claims |
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $5,328 | $118,24637 claims |
| Astellas Pharma US IncIzervay | $1,130 | $33,60014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Wesley Chapel
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.